Acurx Pharmaceuticals, Inc. (ACXP): Price and Financial Metrics

Acurx Pharmaceuticals, Inc. (ACXP): $3.69

0.14 (+3.94%)

POWR Rating

Component Grades













Add ACXP to Watchlist
Sign Up

Industry: Biotech



in industry

ACXP Stock Price Chart Interactive Chart >

Price chart for ACXP

ACXP Price/Volume Stats

Current price $3.69 52-week high $8.74
Prev. close $3.55 52-week low $2.33
Day low $3.61 Volume 6,300
Day high $3.76 Avg. volume 23,166
50-day MA $3.31 Dividend yield N/A
200-day MA $4.10 Market Cap 37.87M

Acurx Pharmaceuticals, Inc. (ACXP) Company Bio

Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.

ACXP Latest News Stream

Event/Time News Detail
Loading, please wait...

ACXP Latest Social Stream

Loading social stream, please wait...

View Full ACXP Social Stream

Latest ACXP News From Around the Web

Below are the latest news stories about Acurx Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACXP as an investment opportunity.

Maxim Group Thinks Acurx Pharmaceuticals’ Stock is Going to Recover

Maxim Group analyst Jason McCarthy reiterated a Buy rating on Acurx Pharmaceuticals (ACXP – Research Report) yesterday and set a price target of $12.00. The company's shares closed last Tuesday at $4.38, close to its 52-week low of $3.71. According to, McCarthy is ranked 0 out of 5 stars with an average return of -10.7% and a 21.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. Currently, the analyst consensus on Acurx Pharmaceuticals is a Moderate Buy with an average price target of $12.00.

Brian Anderson on TipRanks | December 21, 2021

Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI)

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the first patient has been enrolled in its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, against the standard of care to treat CDI, vancomycin, in a 64 patient double-blind randomized trial expected to be completed mid-2022. C. difficile bacteria remains o

Yahoo | December 6, 2021

Acurx Pharmaceuticals (NASDAQ:ACXP) Coverage Initiated at Maxim Group

Maxim Group started coverage on shares of Acurx Pharmaceuticals (NASDAQ:ACXP) in a research note issued to investors on Monday morning, The Fly reports. The brokerage issued a buy rating and a $12.00 target price on the stock. Acurx Pharmaceuticals stock opened at $4.22 on Monday. The businesss 50-day simple moving average is $4.91. Acurx Pharmaceuticals []

Transcript Daily | December 3, 2021

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Director Buys $24,979.24 in Stock

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Director Carl Sailer acquired 5,161 shares of the firm’s stock in a transaction on Tuesday, November 23rd. The stock was purchased at an average price of $4.84 per share, for a total transaction of $24,979.24. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is […]

Dakota Financial News | November 25, 2021

David P. Luci Buys 5,200 Shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Stock

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) CEO David P. Luci bought 5,200 shares of the firms stock in a transaction that occurred on Friday, November 19th. The shares were purchased at an average cost of $4.80 per share, for a total transaction of $24,960.00. The transaction was disclosed in a legal filing with the SEC, which is []

Transcript Daily | November 24, 2021

Read More 'ACXP' Stories Here

ACXP Price Returns

1-mo 41.21%
3-mo 9.82%
6-mo -19.08%
1-year -53.23%
3-year N/A
5-year N/A
YTD -14.61%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.3571 seconds.